← Eichor
Condition: Myeloblastic Leukemia Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Myeloblastic Leukemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of the Relationship Between the Pharmacokinetics (PK) and Pharmacodynamics of Venetoclax in Patients With Acute My
NA · 5 location(s) · Centre Leon Berard · NCT07243483The Effect of Mandala on Anxiety and Fear Levels in Children With Leukemia Before Intrathecal Chemotherapy Treatment
NA · 1 location(s) · Ege University · NCT07203742Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Yo
Phase 2/Phase 3 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT06756152Determination of Epigenetic Markers of Acute Myeloblastic Leukemia in Elderly Patients
NA · 2 location(s) · Groupe Hospitalier de la Region de Mulhouse et Sud Alsace · NCT07250217Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine or CPX-351) in Patients o
Phase 1 · 1 location(s) · Nantes University Hospital · NCT05749276Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Maligna
Phase 4 · 1 location(s) · Gadjah Mada University · NCT07016165Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic
Phase 1/Phase 2 · 2 location(s) · Gyala Therapeutics · NCT07471789
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.